Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nasal Polyps Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

NCT04851964
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Experimental: Tezepelumab, Placebo, Mometasone furoate or equivalent intranasal corticosteroid
Biological · Other · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Birmingham, Alabama • Bakersfield, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 20, 2026, 7:30 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide

NCT03362515
View directory record Official record
Conditions
Nasal Polyps
Interventions
Furosemide, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 20, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Results available

Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery

NCT03228914
View directory record Official record
Conditions
Endoscopic Sinus Surgery, Nasal Polyps
Interventions
Oxymetazoline, Epinephrine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 20, 2026, 7:30 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)

NCT04261582
View directory record Official record
Conditions
Aspirin Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma, Nasal Polyps
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 20, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

NCT01624662
View directory record Official record
Conditions
Bilateral Nasal Polyposis
Interventions
Fluticasone propionate
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Stockton, California • Centennial, Colorado • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 20, 2026, 7:30 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Laser Assisted Treatment of Chronic Sinusitis With and Without Light Activated Agents

NCT00948519
View directory record Official record
Conditions
Rhinosinusitis
Interventions
Laser + ICG, Laser only
Device
Lead sponsor
New York Head & Neck Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 20, 2026, 7:30 PM EDT
Completed Early Phase 1 Interventional

Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis

NCT04583501
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps, Nasal Polyps
Interventions
Omalizumab
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 20, 2026, 7:30 PM EDT
Recruiting Not applicable Interventional

Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis

NCT07290140
View directory record Official record
Conditions
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Interventions
Airiver ESSpand DCB, ESS
Combination Product · Procedure
Lead sponsor
Airiver Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Colorado Springs, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 20, 2026, 7:30 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

NCT04157335
View directory record Official record
Conditions
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Interventions
Benralizumab 30 mg, Matched placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
15
States / cities
Huntington Beach, California • Grand Junction, Colorado • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 20, 2026, 7:30 PM EDT
Withdrawn No phase listed Observational

Association of Periostin Levels and Chronic Sinusitis

NCT02071667
View directory record Official record
Conditions
Sinusitis, Nasal Polyps
Interventions
Blood draw
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 20, 2026, 7:30 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT06706817
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Tezepelumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Newport Beach, California • Chicago, Illinois • Chestnut Hill, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 7:30 PM EDT
Not listed Phase 3 Interventional

Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis

NCT03472144
View directory record Official record
Conditions
Chronic Sinusitis, Ethmoidal, Chronic Sinusitis - Ethmoidal Anterior, Chronic Sinusitis, Chronic Sinusitis - Ethmoidal, Posterior, Chronic Sinusitis, Sphenoidal, Chronic Sinusitis - Frontoethmoidal, Nasal Polyps, Nasal Polyp - Posterior
Interventions
gel loaded with steroids (momentasone), gel loaded with antibiotic (Levofloxacin), gel loaded with both steroids and antibiotic
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 20, 2026, 7:30 PM EDT
Recruiting Not applicable Interventional

3D Printing to Improve Nasal Irrigation Outcome

NCT06118554
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Irrigation head position
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 20, 2026, 7:30 PM EDT
Completed No phase listed Observational Results available

Qualitative Analysis of Subject Experience of Nasal Polyps

NCT03221192
View directory record Official record
Conditions
Nasal Polyps
Interventions
VAS questionnaire, SNOT-22 questionnaire, Data capture app
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 20, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

NCT05274750
View directory record Official record
Conditions
Nasal Polyps
Interventions
Depemokimab (GSK3511294), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 20, 2026, 7:30 PM EDT
Terminated Phase 1 Interventional Results available

Trial of Topical Verapamil in Chronic Rhinosinusitis With Nasal Polyps

NCT03102190
View directory record Official record
Conditions
Sinusitis, Nasal Polyps
Interventions
Verapamil Hydrochloride Intranasal
Drug
Lead sponsor
Benjamin Bleier
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 20, 2026, 7:30 PM EDT
Completed Phase 2 Interventional

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

NCT06013241
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Brensocatib, Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
27
States / cities
Tucson, Arizona • Roseville, California • Upland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

NCT01622569
View directory record Official record
Conditions
Bilateral Nasal Polyposis
Interventions
Fluticasone Propionate
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Tucson, Arizona • Bakersfield, California • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 20, 2026, 7:30 PM EDT
Withdrawn No phase listed Observational

Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab

NCT03369574
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Asthma, Nasal Polyps
Interventions
Reslizumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 20, 2026, 7:30 PM EDT
Completed Phase 2 Interventional

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

NCT06691113
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Murrieta, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 20, 2026, 7:30 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834360
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • La Mesa, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 20, 2026, 7:30 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Integrated Cancer Repository for Cancer Research

NCT02012699
View directory record Official record
Conditions
Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 110 Years
Enrollment
999,999 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
42
States / cities
Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 20, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

NCT03280550
View directory record Official record
Conditions
Nasal Polyps, Chronic Rhinosinusitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Roseville, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 20, 2026, 7:30 PM EDT
Completed No phase listed Observational

DNA Microarray Analysis of Gene Expression in Chronic Rhinosinusitis

NCT01001819
View directory record Official record
Conditions
Chronic Rhinosinusitis w/o Nasal Polyps
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 20, 2026, 7:30 PM EDT